The Quantellect read.As of Nov 19, 2026, 17 active firms cover Edwards Lifesciences Corp: 14 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $85.00 to $110.00, so the covering firms are broadly aligned. The average target of $101.94 sits 3% below the current $105.25. The rating mix has stayed broadly stable, with Buy-side ratings easing from 15 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.84 next quarter toward $3.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 active firms
Buy
Strong Buy00%
Buy1482%
Neutral318%
Sell00%
Strong Sell00%
Based on 17 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$101.94
-3.1% downside
Average target across 17 active firms as of Nov 19, 2026 vs $105.25 current
Highest Target$110.00
Average Target$101.94
Lowest Target$85.00
Detailed analyst forecasts for EW
Showing 1–19 of 19 named analysts shown · 17 active firms in the rating projection
As of Nov 19, 2026, 14 of 17 active firms rate EW a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
EW EPS & revenue forecast
EPS · NEXT QUARTER
$0.84
Range $0.77 – $0.90 · 19 analysts · +8% YoY
Next period, 19 analysts expect Edwards Lifesciences Corp to earn $0.84 a share (range $0.77 – $0.90), versus $0.78 a year earlier. Full-year consensus is $3.01, growing to $3.39 the year after.
REVENUE · NEXT QUARTER
$1.8B
Range $1.8B – $1.8B · 19 analysts · +9% YoY
Revenue is expected to reach $1.8B (range $1.8B – $1.8B), +8.9% year-over-year. Full-year consensus is $6.8B, rising to $7.5B next year.
Top analysts covering Edwards Lifesciences Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EW.
#1
Joanne Wuensch
Citigroup · Rank #35
Buy
$117.00+11.2% to target
Overall win rate
51%
+ Follow
#2
Anthony Petrone
Mizuho · Rank #121
Buy
$105.00-0.2% to target
Overall win rate
45%
+ Follow
#3
JB
Jayson Bedford
Raymond James · Rank #191
Buy
$96.00-8.8% to target
Overall win rate
44%
+ Follow
#4
Vijay Kumar
Evercore ISI Group · Rank #331
Buy
$100.00-5.0% to target
Overall win rate
36%
+ Follow
#5
William Plovanic
Canaccord Genuity · Rank #370
Neutral
$97.00-7.8% to target
Overall win rate
38%
+ Follow
EW stock forecast FAQ
What is EW's average 12-month price target?+
The 17 active firms with a live target average $101.94 for Edwards Lifesciences Corp over the next 12 months, ranging from a $110.00 high to a $85.00 low, as of Nov 19, 2026.
Is EW stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 17 active firms as of Nov 19, 2026, 14 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for EW?+
The Street-high target is $110.00 (Barclays), and the Street-low is $85.00 (Canaccord Genuity). The average of all 17 active-firm targets is $101.94.
How many active Wall Street firms cover EW?+
17 active firms have a recognized rating on Edwards Lifesciences Corp as of Nov 19, 2026, and 17 active firms carry a live 12-month price target.
Who is the most accurate analyst covering EW?+
Among analysts who currently cover EW, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $117.00 target.
What is Edwards Lifesciences Corp's projected EPS for next quarter?+
The consensus estimate is $0.84 per share (range $0.77 – $0.90) across 19 analysts. Full-year EPS is projected at $3.01, rising to $3.39 the following year.
How much revenue is Edwards Lifesciences Corp expected to report next quarter?+
Consensus revenue is $1.8B (range $1.8B – $1.8B). Full-year revenue is projected at $6.8B, growing to $7.5B next year.
Have analysts been upgrading or downgrading EW lately?+
As of Nov 19, 2026, 14 of 17 active firms rate EW a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EW calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.